Drug intelligence / Profile preview

DTaP-IPV-HepB-Hib Vaccine

Development stage: Preclinical
Lead developer: Vaccine Industrial Holding
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A hexavalent combination vaccine developed by Vaccine Industrial Holding (VIC) for the prevention of six major infectious diseases: diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease caused by *Haemophilus influenzae* type b (Hib). The vaccine is designed to simplify pediatric immunization schedules by combining multiple antigens into a single injection. It typically contains diphtheria and tetanus toxoids, acellular pertussis antigens, inactivated poliovirus (IPV) types 1, 2, and 3, recombinant hepatitis B surface antigen (HBsAg), and Hib capsular polysaccharide. VIC is a Saudi Arabian biomanufacturing company focused on localizing the production of these essential vaccines within the Kingdom of Saudi Arabia through technology transfer and strategic partnerships.

Other names: DTaP-IPV-HepB-Hib Combination VaccineHexavalent vaccinediphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + hepatitis B vaccine + haemophilus influenzae type b vaccine

Targets

PV (Poliovirus (Types 1, 2, and 3))HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on DTaP-IPV-HepB-Hib Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTaP-IPV-HepB-Hib Vaccine.

Explore the full profile